Lack of Association of the NPAS2 Gene Ala394Thr Polymorphism (rs2305160:G>A) with Risk of Chronic Lymphocytic Leukemia |
Rana, Sobia
(Department of Physiology and Cell Biology, University of Health Sciences)
Shahid, Adeela (Department of Physiology and Cell Biology, University of Health Sciences) Ullah, Hafeez (Department of Allied Health Sciences, University of Health Sciences) Mahmood, Saqib (Department of Human Genetics & Molecular Biology, University of Health Sciences) |
1 | Asher G, Schibler U (2006). A CLOCK-less clock. Trends Cell Biol, 16, 547-49. DOI |
2 | Bartsch C, Bartsch H, Schmidt A, et al (1992). Melatonin and 6-sulfatoxymelatonin circadian rhythms in serum and urine of primary prostate cancer patients: evidence for reduced pineal activity and relevance of urinary determinations. Clin Chim Acta, 209, 153-67. DOI |
3 | Yi CH, Zheng T, Leaderer D, Hoffman A, Zhu Y (2009). Cancerrelated transcriptional targets of the circadian gene NPAS2 identified by genome-wide ChIP-on-chip analysis. Cancer Lett, 284, 149-56. DOI |
4 | Yi C, Mu L, de la Longrais IA, et al (2010). The circadian gene NPAS2 is a novel prognostic biomarker for breast cancer. Breast Cancer Res Treat, 120, 663-69. DOI ScienceOn |
5 | Yuan P, Wang S, Zhou F, et al (2014). Functional polymorphisms in the NPAS2 gene are associated with overall survival in transcatheter arterial chemoembolization- treated hepatocellular carcinoma patients. Cancer Sci, 105, 825-32. DOI |
6 | Zhou YD, Barnard M, Tian H, et al (1997). Molecular characterization of two mammalian bHLH-PAS domain proteins selectively expressed in the central nervous system. Proc Natl Acad Sci USA, 94,713-18. DOI |
7 | Zhu Y, Leaderer D, Guss C, et al (2007). Ala394Thr polymorphism in the clock gene NPAS2: a circadian modifier for the risk of non-Hodgkin's lymphoma. Int J Cancer, 120, 432-35. DOI |
8 | Zhu Y, Stevens RG, Leaderer D, et al (2008). Non-synonymous polymorphisms in the circadian gene NPAS2 and breast cancer risk. Breast Cancer Res Treat, 107, 421-5. DOI |
9 | Chen-Goodspeed M, Lee CC (2007). Tumor suppression and circadian function. J Biol Rhythms, 22, 291-98. DOI |
10 | Bertolucci C, Cavallari N, Colognesi I, et al (2008). Evidence for an overlapping role of CLOCK and NPAS2 transcription factors in liver circadian oscillators. Mol Cell Biol, 28, 3070-75. DOI |
11 | Chu LW, Zhu Y, Yu K, et al (2008). Variants in circadian genes and prostate cancer risk: a population-based study in China. Prostate Cancer Prostatic Dis, 11, 342-48. DOI |
12 | DeBruyne JP, Weaver DR, Reppert SM (2007). CLOCK and NPAS2 have overlapping roles in the suprachiasmatic circadian clock. Nat Neurosci, 10, 543-45. DOI ScienceOn |
13 | Dohner H, Stilgenbauer K, Dohner M (1999). Chromosome aberrations in B-cell chronic lymphocytic leukemia: reassessment based on molecular cytogenetic analysis. J Mol Med, 77, 266-81. DOI |
14 | Fujino Y (2007). Occupational factors and mortality in the Japan Collaborative Cohort Study for Evaluation of Cancer (JACC). Asian Pac J Cancer Prev, 8, 97-104. |
15 | Fu L, Lee CC (2003). The circadian clock: pacemaker and tumour suppressor. Nat Rev Cancer, 3, 350-61. DOI |
16 | Fu L, Pelicano H, Liu J, Huang P, Lee C (2002). The circadian gene Period2 plays an important role in tumor suppression and DNA damage response in vivo. Cell, 111, 41-50. DOI ScienceOn |
17 | Hoffman AE, Zheng T, Ba Y, Zhu Y (2008). The circadian gene NPAS2, a putative tumor suppressor, is involved in DNA damage response. Mol Cancer Res, 6, 1461-68. DOI |
18 | Howlader N, Noone AM, Krapcho M, et al (2012). SEER Cancer Statistics Review 1975-2009 (Vintage 2009 Populations). National Cancer Institute, Bethesda, MD. http:// seer.cancer.gov. |
19 | Kucuktulu E (2012). Protective effect of melatonin against radiation induced nephrotoxicity in rats. Asian Pac J Cancer Prev, 13, 4101-05. DOI ScienceOn |
20 | Kermani IA, Dehdilani M, Dolatkhah R (2007). Chronic lymphocytic leukemia in the recent 10 years and treatment effects of Fludarabin. Asian Pac J Cancer Prev, 8, 367-71. |
21 | Luo Y, Wang F, Chen LA, et al (2012). Deregulated expression of cry1 and cry2 in human gliomas. Asian Pac J Cancer Prev, 13, 5725-28. 과학기술학회마을 DOI ScienceOn |
22 | Mirick DK, Davis S (2008). Melatonin as a biomarker of circadian dysregulation. Cancer Epidemiol Biomarkers Prev, 17, 3306-13. DOI |
23 | Oscier D, Fegan C, Hillmen P, et al (2004). British Committee for Standards in Haematology. Guidelines on the diagnosis and management of chronic lymphocytic leukaemia. Br J Haematol, 125, 294-317. DOI |
24 | Schernhammer ES, Hankinson SE (2009). Urinary melatonin levels and postmenopausal breast cancer risk in the Nurses' Health Study cohort. Cancer Epidemiol Biomarkers Prev, 18, 74-9. DOI ScienceOn |
25 | Sgambati MT, Linet MS, Devesa SS (2001). Chronic Lymphocytic Leukemia: Epidemiological, Familial, and Genetic Aspests. In 'Chronic Lymphoid Leukemias', Eds Cheson BD, Marcel Dekker, New York pp 33-62. |
26 | Straif K, Baan R, Grosse Y (2007). Carcinogenicity of shiftwork, painting, and fire-fighting. Lancet Oncol, 8, 1065-66. DOI ScienceOn |
27 | Wang F, Hu Z, Yang R, et al (2011). A variant affecting miRNAs binding in the circadian gene neuronal PAS domain protein 2 (NPAS2) is not associated with breast cancer risk. Breast Cancer Res Treat, 127, 769-75. DOI |
28 | Costa G, Haus E, Stevens R (2010). Shift work and cancer - considerations on rationale, mechanisms, and epidemiology. Scand J Work Environ Health, 36, 163-79. DOI |
29 | Mozaheb Z, Hasanzadeh NazarAbadi MH, Aghaee MA (2012). Chronic lymphocytic leukemia and prognostic factors. Asian Pac J Cancer Prev, 13, 3009-13. 과학기술학회마을 DOI |